Eupraxia Pharmaceuticals Inc. (EPRX): Cantor Fitzgerald Sees 108% Price Potential!
Reading Time: 2 minutes
Currently, Eupraxia Pharmaceuticals Inc. (EPRX) is standing out positively. The biotech company specializes in the development of locally administered drugs with extended release of active ingredients. At the core of its corporate strategy is the proprietary Diffusphere technology, designed to enable precise and long-lasting drug effects with minimized systemic side effects. This innovative platform could be utilized for a variety of indications and drugs, offering the company broad future development opportunities. Investors should keep an eye...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
